NAVLIN Daily NewsCheckout Today’s News
A total of 107 drugs were added to China's National Reimbursement Drug List (NRDL), around half of which are innovative Category 1 drugsJW Therapeutics’ Carteyva (relma-cel) for lymphoma, has become the first CAR-T cell therapy to enter the NRDL after transitioning from last year’s Commercial Insurance Innovative Drug List. Its reimbursement standard is reportedly RMB 288,600 (~$43,257 at the time of publication) per doseThis year’s commercial list features 12 additions, including the world’s first approved solid tumor CAR-T therapy, CARsgen Therapeutics Holdings’ satricabtagene autoleucel injection
Last week, NAVLIN Daily brought you key market access developments from across the globe In the U.S., officials are expected to meet with the German government amid continued pressure over pharmaceutical pricing policies and an ongoing Section 301 trade investigation. Meanwhile, the EC published its fifth JCA under the EU HTA Regulation, covering AstraZeneca’s Etcamah (camizestrant)At ISPOR Europe 2026, experts warned that MFN pricing could reshape global drug launch strategies and influence market-entry decisions
Japan plans to make drug discovery and pharmaceutical innovation priority investment areas in its growth strategy through 2040The government aims to boost economic growth, strengthen health and medical security, and establish Japan as a global pharmaceutical innovation hubJapan targets $146.7 billion in public-private investment by 2040, with plans to double international joint clinical trials and strengthen support for innovative medicines and regenerative medicine
Japan plans to delist 657 drug products from its NHI price list, including ActHIB, Alofisel, and XolairManufacturers requested discontinuation, citing factors including the loss of medical demandA total of 610 products have alternatives with the same active ingredient, while 47 will be delisted at the ingredient level. A grace period will run through March 2027
UAE becomes the first country globally to conditionally approve Ultomiris (ravulizumab) for a new IgA nephropathy indicationThe approval allows treatment to reduce proteinuria in adults at risk of disease progressionThe EDE approved, expanding the use of AstraZeneca's Ultomiris, which has been registered in the UAE since 2022
The European Parliament has adopted a resolution on the implementation of Europe’s Beating Cancer Plan (EBCP), calling for at least EUR 2.5 billion in dedicated funding under the EU’s next Multiannual Financial Framework (MFF) for 2028 to 2034The resolution, approved by 447 votes in favor, 66 against, and 91 abstentions, seeks to safeguard cancer-related funding, improve access to treatments and strengthen monitoring of patient outcomes. The majority of votes against were due to the tobacco provisions in the planMEPs called for greater cooperation between Member States to address inequalities in cancer screening, diagnosis, and treatment, particularly for patients with rare and childhood cancers. The Parliament also supported improved access to clinical trials and innovative therapies, including cross-border treatment opportunities, alongside dedicated support for specialist cancer care and research

The Irish Presidency of the Council of the European Union has maintained a proposed 12-month extension of supplementary protection certificates (SPCs) for certain innovative biotechnology medicines in its latest compromise text on the European Biotech Act, as negotiations continue among Member States over incentives for pharmaceutical innovation and the protection of intellectual propertyUnder the compromise, eligible medicines must meet requirements relating to therapeutic innovation, clinical trials in at least three EU Member States and manufacturing within the EU. The European Medicines Agency (EMA) would assess compliance, while national authorities could revoke extensions if manufacturing requirements are no longer met. The Presidency also proposes extending the six-month manufacturing and stockpiling period for biosimilars, although the new duration remains undecidedSeparately, Spain's Ministry of Health has confirmed to Diario Farma that its proposed European Coordinated Market Access Toolbox has been discussed within the Council and is being examined by the relevant working groups. The voluntary initiative would introduce demand-side incentives, including coordinated negotiations, collaborative procurement, and early market access arrangements, without replacing national pricing and reimbursement powers
At the FT Global Pharma and Biotech Summit, industry leaders from Bayer, EFPIA and MSD discussed U.S. Most Favored Nation (MFN) pricing pressure as a key factor in determining Europe’s viability for innovation, investment, launches and partnerships compared with the U.S. and ChinaTomer Feffer, CEO UK & Ireland and Head of Region Northeast-Central Europe at Bayer, described MFN as “a gift for us all” because it creates an opportunity to revisit the societal agreements underpinning European healthcare, including the Bismarckian insurance model, pointing to long waits for doctors and surgery and patients receiving less than half of available treatmentsNathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), said Europe has rested on its laurels while China and the U.S. have moved aggressively, citing capital markets investment at roughly one-tenth of U.S. levels and the risk of losing manufacturing
During a hearing led by the Committee on Public Health Ordinary of the European Parliament, Dr. Vanessa Gregorc explained that the U.S. Most Favored Nation (MFN) policy has slowed EU access to advanced therapies. She urged streamlined EU trials and better funding to stay competitive with the U.S., China, and JapanProfessor Domas Vaitiekus then highlighted Lithuania's solution for smaller markets. With no access to commercial CAR-T therapies, Lithuania uses hospital exemptions to produce affordable, in-house treatments (€130,000/patient)Professor Miguel Forte later emphasized the need to work together across the EU to improve access to advanced treatments. He called for permanent investment in biotech and funding for early-stage development to avoid the "valley of death." Forte also called for specialized centers of excellence to collaborate, not compete

The European Commission has published the fifth Joint Clinical Assessment (JCA) under the EU HTA Regulation for AstraZeneca's Etcamah (camizestrant), which in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during first-line endocrine therapy in combination with a CDK4/6 inhibitor, without disease progressionFollowing a revision of Etcamah's proposed indication in January 2026, two of the seven originally defined PICOs were removed from the assessment scope, narrowing the JCA's focus to patient populations and comparators aligned with the final approved indicationThe phase 3 SERENA-6 trial showed that Etcamah improved progression-free survival and second progression-free survival versus continued aromatase inhibitor therapy, while the report highlighted uncertainties around the novel ESR1 mutation-guided early-switch treatment strategy, repeated testing requirements and long-term treatment sequencing